InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Commitments Test Entity - Second Quarter Report 31 Jan 2006 11:32AM $1.945 $0.027 fallen by 98.61%
- Signs first distributor for Aridol 18 Jan 2006 9:57AM $1.975 $0.027 fallen by 98.63%
- Bronchitol European Cystic Fibrosis Study Commences 16 Dec 2005 12:07PM $1.990 $0.027 fallen by 98.64%
- U.S. Phase III Aridol Trial Enrols First Patent 14 Dec 2005 9:43AM $1.900 $0.027 fallen by 98.58%
- Bronchitol Cystic Fibrosis Dose Finding Study Commences 28 Nov 2005 11:06AM $2.250 $0.027 fallen by 98.80%
- Bronchitol Granted Orphan Drug Status in Europe 14 Nov 2005 11:15AM $2.290 $0.027 fallen by 98.82%
- Pharmaxis announces pricing of Global Capital Raising 8 Nov 2005 4:18PM n/a $0.027 n/a
- Trading Halt 7 Nov 2005 9:30AM n/a $0.027 n/a
- Commitments Test Entity - First Quarter Report 25 Oct 2005 8:32AM $2.520 $0.027 fallen by 98.93%
- Global Capital Raising 26 Sep 2005 9:27AM $2.600 $0.027 fallen by 98.96%
- Enrolment Commenced in Aridol COPD Study 15 Sep 2005 11:06AM $2.200 $0.027 fallen by 98.77%
- Bronchitol Cystic Fibrosis Trial Results Positive 31 Aug 2005 9:43AM $2.410 $0.027 fallen by 98.88%
- Preliminary Final Report 30 Aug 2005 11:37AM $2.200 $0.027 fallen by 98.77%
- Commitments Test Entity - Fourth Quarter Report 29 Jul 2005 1:38PM $1.750 $0.027 fallen by 98.46%
- Approval to Begin Canadian Cystic Fibrosis Trial Granted 21 Jul 2005 8:57AM $1.690 $0.027 fallen by 98.40%
- FDA grants Bronchitol orphan drug status for Cystic Fibrosis 20 Jul 2005 9:14AM $1.670 $0.027 fallen by 98.38%
- Response to ASX Share Price Query 23 Jun 2005 9:32AM $1.590 $0.027 fallen by 98.30%
- Cystic Fibrosis Trial reaches target recruitment 29 Apr 2005 1:17PM $1.270 $0.027 fallen by 97.87%
- Response to ASX Share Price Query 4 Mar 2005 11:38AM $1.250 $0.027 fallen by 97.84%
- US FDA Grants Bronchitol Orhpan Drug Status 23 Feb 2005 12:54PM $1.070 $0.027 fallen by 97.48%
- US FDA Grants Approval For Aridol Phase III Trial 23 Dec 2004 8:55AM $0.780 $0.027 fallen by 96.54%
- Secures US patent for multiple sclerosis treatment 26 Nov 2004 11:26AM $0.850 $0.027 fallen by 96.82%
- Placement of $16.5 Million & Share Purchase Plan 3 Nov 2004 8:54AM $0.780 $0.027 fallen by 96.54%
- Trading Halt 1 Nov 2004 8:49AM n/a $0.027 n/a
- Successfully Completes Enrolment for Phase 111 Trial Aridol 30 Jul 2004 9:28AM $0.550 $0.027 fallen by 95.09%

801 - 825 of 836 results

Page 33 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.